Publications by authors named "Taiya Bach"
Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.
J Pediatr Gastroenterol Nutr
December 2024
Article Synopsis
- A study on infants with cystic fibrosis (CF) examined the impact of acid blocker therapy (ABT) on growth, gut microbiome (GM), and early lung disease, finding that over half of the participants used ABT by age 3.* -
- Although ABT use was more prevalent among children with pancreatic insufficiency, it did not lead to significant growth improvements; instead, it was linked to lower GM diversity and more severe lung disease.* -
- The research highlights the need for careful evaluation of ABT's risks and benefits, suggesting that current treatment guidelines for young children with CF require reevaluation.*
Background: The 2009 cystic fibrosis (CF) infant care guidelines recommend breastmilk as the initial feeding but do not address if/when it should be fortified or supplemented with formula to promote optimal growth and pulmonary health.
Methods: We conducted a prospective multi-center cohort study in breastfed and formula-fed infants that included 172 infants with CF who were born during 2012-17, enrolled after newborn screening at age 1.9 ± 1.
Background: The variable response to fat-soluble vitamin supplementation in young children with cystic fibrosis (CF), and factors contributing to this variability, remain under-investigated.
Objective: To determine if recommended supplement doses normalize serum vitamins A (retinol), D (25-hydroxy-vitamin D, 25OHD), and E (α-tocopherol), and identify factors predictive of achieving sufficiency, in children with CF in the first 3 years of life.
Design: We studied 144 infants born during 2012-2017 and diagnosed with CF through newborn screening.